Researchers from University of South Carolina (USC) in the US identified a novel human protein variant that can be targeted to prevent the human immunodeficiency virus from harming HIV-positive individuals.
"Most HIV drugs target the virus but the virus is not stable, it always mutates - problematic because the virus can become resistant to effective drugs," said I-Chueh Huang, assistant professor at USC.
The new study focused on HIV-1, the most widespread version worldwide.
Detection of X4 is an indication that the patient's HIV infection has progressed to a very toxic state.
Researchers identified a novel variant within the previously identified family of proteins.
They nicknamed it "Delta 20," an immune system protein that suppresses the most damaging HIV strains, X4, by preventing the virus from infecting cells.
This method differs from the more traditional method of targeting viruses that may eventually become resistant to specific medical therapies, researchers said.
"Our finding will not help develop a vaccine because the focus is on innate immunity rather than the virus," Huang said.
"Perhaps one day scientists will create medicine that, like 'HIV cocktails,' have to be taken indefinitely. But the new treatment may be more effective because it is harder for viruses to escape the body's defences," Huang added.
The study was published in the journal Proceedings of the National Academy of Sciences.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
